Depression and cancer: Recent data on clinical issues, research challenges and treatment approaches

Current Opinion in Oncology

Volumn 20, Issue 4, 2008, Pages 353-359

  Reich, Michel ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Antidepressants; Cancer; Depression; Psychosocial interventions; Suicide

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; DESIPRAMINE; ESTROGEN RECEPTOR; FLUOXETINE; PAROXETINE; RALOXIFENE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN;

ANHEDONIA; ANOREXIA; BREAST CANCER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER SCREENING; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DISTRESS SYNDROME; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; GROUP THERAPY; GUILT; HELPLESSNESS; HOPELESSNESS; HORMONAL THERAPY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HOT FLUSH; HUMAN; INTERPERSONAL COMMUNICATION; LIFE STRESS; LONELINESS; LOW DRUG DOSE; MENTAL HEALTH; NEOPLASM; NEUROENDOCRINOLOGY; NEUROIMAGING; NEUROIMMUNOLOGY; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOLOGY; PSYCHOPHYSIOLOGY; PSYCHOTHERAPY; RELIGION; REVIEW; SELF ESTEEM; SLEEP DISORDER; SOCIAL SUPPORT; SUICIDAL IDEATION; WEIGHT REDUCTION; PATHOPHYSIOLOGY;

DEPRESSIVE DISORDER; HUMANS; NEOPLASMS;

EID: 47249105676     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282fc734b     Document Type: Review

References (71)

1. Pasquini M, Biondi M. Depression in cancer patients: a critical review. Clin Pract Epidemol Ment Health 2007; 3:2. This article reviews through the literature recent findings on depression and cancer with interesting highlights on biological correlates, risk factor and unmet needs of cancer depressed patients.
2. Hopko DR, Bell JL, Armento ME, et al. The phenomenology and screening of clinical depression in cancer patients. J Psychosoc Oncol 2008; 26:31-51. This article emphasizes on the usefulness of screening tools and their strong psychometric properties, such as CES-D, Beck Depression Inventory-II (BDI-II) and HRSD in cancer patients.
3. Ronson A. Psychiatric disorders in oncology: recent therapeutic advances and new conceptual frameworks. Curr Opin Oncol 2004; 16:318-323.
4. Wilson KG, Chochinov HM, Skirko MG, et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 2007; 33:118-129. This survey was conducted by the Canadian National Palliative Care with semi-structured interviews to a large cohort of 381 patients receiving palliative care and emphasizes on the importance of depression and anxiety screening among them and even those in terminal care.
5. Lee KC, Ray GT, Hunkeler EM, Finley PR. Tamoxifen treatment and new-onset depression in breast cancer patients. Psychosomatics 2007; 48:205-210. In this huge retrospective cohort study involving 2943 breast cancer patients, the risk of new onset depression was correlated with estrogen-receptor protein status (ER+) independent of tamoxifen exposure.
6. McCaffrey JC, Weitzner M, Kamboukas D, et al. Alcoholism, depression, and abnormal cognition in head and neck cancer: a pilot study. Otolaryngol Head Neck Surg 2007; 136:92-97.
7. Bottomley A. Depression in cancer patients: a literature review. Eur J Cancer Care 1998; 7:181-191.
8. Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer 2007; 110:1665-1676. This article reviews the recent literature on psychiatric disorders and emphasizes on screening and initiating first line treatments for depression.
9. Grabsch B, Clarke DM, Love A, et al. Psychological morbidity and quality of life in women with advanced breast cancer: a cross-sectional survey. Palliat Support Care 2006; 4:47-56.
10. Palesh OG, Collie K, Batiuchok D, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol 2007; 75:37-44. In this longitudinal study of 93 metastatic breast cancer patients, a relationship is found between the clinical features of sleep disturbance and psychosocial factors (depression and stress) and pain. Disturbed sleep could be a specific clinical marker for these symptoms in the advanced cancer population. Group therapy intervention did not improve sleep problems but initially, it was not targeted for that. Still, this study might have important implications in a better understanding of several patterns of sleep disturbance.
11. Lloyd-Williams M, Shiels C, Dowrick C. The development of the Brief Edinburgh Depression Scale (BEDS) to screen for depression in patients with advanced cancer. J Affect Disord 2007; 99 (1-3):259-264. This paper is focusing on the psychometric properties of the BEDS. It is a 6-item depression scale that can represent a good screening tool with a sensitivity of 72% and specificity of 83% that may have a significant impact on the assessment and management of depression in advanced cancer.
12. Chochinov HM, Wilson KG, Enns M, Lander S. 'Are you depressed?' Screening for depression in the terminally ill. Am J Psychiatry 1997; 154:674-676.
13. Lloyd-Williams M, Dennis M, Taylor F, Baker I. Is asking patients in palliative care 'are you depressed?' appropriate? Prospective study. BMJ 2003; 327:372-373.
14. Walker J, Postma K, McHugh GS, et al. Performance of the Hospital Anxiety and Depression Scale as a screening tool for major depressive disorder in cancer patients. J Psychosom Res 2007; 63:83-91. This study used HADS to explore depression screening among 361 consecutive patients attending a regional cancer center in Edinburgh. In spite of a low rate of major depressive disorder (30/361 = 8.3%), the authors found that a cut-off of 14/15 gave a sensitivity of 0.87 (95% CI: 0.70-0.95) and a specificity of 0.85 (95% CI: 0.81-0.89) and recommend HADS as a good screening tool for major depressive disorders in oncology.
15. Teunissen SC, de Graeff A, Voest EE, de Haes JC. Are anxiety and depressed mood related to physical symptom burden? A study in hospitalized advanced cancer patients. Palliat Med 2007; 21:341-346. This study using two scales (HADS, Edmonton Symptom Assessment System) and a single item question (Are you anxious and/or depressed?) failed to demonstrate the possible link between psychosocial parameters such as anxiety and depression and the presence and intensity of physical symptoms in 79 hospitalized advanced cancer patients.
16. Pasquini M, Biondi M, Costantini A, et al. Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depress Anxiety 2006; 23:441-448.
17. Guo Y, Musselman DL, Manatunga AK, et al. The diagnosis of major depression in patients with cancer: a comparative approach. Psychosomatics 2006; 47:376-384.
18. Sharpley CF, Christie DRH. An analysis of the psychometric profile and frequency of anxiety and depression in Australian men with prostate cancer. Psychooncology 2007; 16:660-667. This is an extensive study done in a sample of Australian men with prostate cancer (n = 195) to assess the prevalence of anxiety and depression, their underlying component structure and ways of dealing with those symptoms. For this, two specific scales self-rating anxiety scale (SAS) and self-rating depression scale (SDS) developed by Zung WWK were used.
19. Somerset W, Stout SC, Miller AH, Musselman D. Breast cancer and depression. Oncology 2004; 18:1021-1034.
20. Frick E, Tyroller M, Panzer M. Anxiety, depression and quality of life of cancer patients undergoing radiation therapy: a cross-sectional study in a community hospital outpatient centre. Eur J Cancer Care 2007; 16:130-136. This is the first study that advocates that psycho-oncological assessment should address psychopathological comorbidity (anxiety and depression) and both health-related quality of life and individual quality of life among cancer patients undergoing radiotherapy, with diagnostic and therapeutic advantages.
21. Monahan PO, Champion V, Rawl S, et al. What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-posttreatment depressive symptoms or type of treatment? Qual Life Res 2007; 16:399-411. This study demonstrates an independent contribution of depressive symptoms and treatment type in predicting several components of quality of life outcomes in 105 clinically localized prostate cancer patients. Conclusions give recommendations to healthcare providers to assess depressive symptoms before and after treatment completion.
22. Reich M, Lesur A, Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat 2007. [Epub ahead of print]
23. Falagas ME, Zarkadoulia EA, Ioannidou EN, et al. The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Res 2007; 9:R44. This is a review of relevant studies to explain the possible link between psychosocial factors (e.g. depression) and breast cancer survival. Regarding depression, the authors found four studies with a negative impact, one with a positive impact and five without any impact.
24. Onitilo AA, Nietert PJ, Egede LE. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 2006; 28:396-402.
25. Lehto US, Ojanen M, Dyba T, et al. Baseline psychosocial predictors of survival in localized melanoma. J Psychosom Res 2007; 63:9-15. This study analyzes the impact on survival of type C response style, which reflects emotional nonexpression among 59 patients with localized melanoma. The authors found that baseline psychological variables related to the cancer-prone type C response pattern could be a predictor of shorter survival.
26. Lehto US, Ojanen M, Dyba T, et al. Baseline psychosocial predictors of survival in localized breast cancer. Br J Cancer 2006; 94:1245-1252.
27. Chen ML, Chang HK. Physical symptom profiles of depression and non-depressed patients with cancer. Palliat Med 2004; 18:712-718.
28. Polsky D, Doshi JA, Marcus S, et al. Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med 2005; 165:1260-1266.
29. Lefetz C, Reich M. Suicidal crisis in oncology: assessment and care. Bull Cancer 2006; 93:709-713.
30. Labisi O. Assessing for suicide risk in depressed geriatric cancer patients. J Psychosoc Oncol 2006; 24:43-50.
31. Land SR, WickerHam DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2742-2751.
32. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003; 54:283-294.
33. Yoshikawa E, Matsuoka Y, Yamasue E, et al. Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosis. Biol Psychiatry 2006; 59:707-712.
34. Kumano H, Ida I, Oshima A, et al. Brain metabolic changes associated with predisposition to onset of major depressive disorder and adjustment disorder in cancer patients: a preliminary PET study. J Psychiatr Res 2007; 41:591-599. This is an interesting preliminary study that tends to correlate in cancer patients neurobiological risk factors for depressive disorders or adjustment disorders and regional brain metabolism with neuroimaging changes [18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET)]. Even if the sample is small, that is, 10 with mood deterioration and nine without mood disorders, results on the PET seem to have clinical implications in terms of vulnerability to develop further depression screening.
35. Inagaki M, Yoshikawa E, Kobayakawa M, et al. Regional cerebral glucose metabolism in patients with secondary depressive episodes after fatal pancreatic cancer diagnosis. J Affect Disord 2007; 99 (1-3):231-236.
36. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003; 17:S119-S124.
37. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9:46-56. This article gives a new immunologic theory that involves inflammation to explain high prevalence of depressive symptoms in physically ill patients. The authors concluded that besides traditional psychosocial factors, inflammation as a biological event must be taken into account among all the potential factors that might increase the risk of depression.
38. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007; 21:374-383. This is an excellent article that reviews all the recent theories between depression and immune system and articulate depression with brain and behavior through the immune system. The authors emphasize multiple translational targets derived from the cytokine model of depression work, which could open the way for new drug targets development with a clinical impact.
39. Soygur H, Palaoglu O, Akarsu ES, et al. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1242-1247.
40. Jehn CF, Kuehnhardt D, Bartholomae A, et al. Biomarkers of depression in cancer patients. Cancer 2006; 107:2723-2729.
41. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000; 92:994-1000.
42. Reiche EM, Morimoto HK, Nunes SM. Stress and depression-induced immune dysfunction: implications for the development and progression of cancer. Int Rev Psychiatry 2005; 17:515-527.
43. Abercrombie HC, Janine Giese-Davi J, Sephton S, et al. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 2004; 29:1082-1092.
44. Vedhara K, Stra JT, Miles JN, et al. Psychosocial factors associated with indices of cortisol production in women with breast cancer and controls. Psychoneuroendocrinology 2006; 31:299-311.
45. Osborne RH, Sali A, Aaronson NK, et al. Immune function and adjustment style: do they predict survival in breast cancer? Psychooncology 2004; 13:199-210.
46. Simon NM, Smoller JW, McNamara KL, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 2006; 60:432-435.
47. Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 2006; 94:372-390.
48. Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer patients: a systematic review. Support Care Cancer 2007; 15:123-136. This article provides an extensive review of pharmacological and nonpharmaco-logical treatments for depression in oncology published since 2005. The review is well conducted with reliable methodologies.
49. Kim HF, Fisch MJ. Antidepressant use in ambulatory cancer patients. Curr Oncol Rep 2006; 8:275-281.
50. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758-1764.
51. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97:30-39.
52. Fulton-Kehoe D, Rossing MA, Rutter C, et al. Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 2006; 94:1071-1078.
53. Chien C, Li CI, Heckbert SR, et al. Antidepressant use and breast cancer risk. Breast Cancer Res Treat 2006; 95:131-140.
54. Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 2007.[Epub ahead of print]
55. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitripty-line. Breast Cancer Res Treat 2001; 70:1-10.
56. Holland JC, Romano SJ, Heiligenstein JH, et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998; 7:291-300.
57. Musselman DL, Somerset WI, Guo Y, et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III and IV) with major depression. J Clin Psychiatry 2006; 67:288-296.
58. Stockler MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol 2007; 8:603-612.
59. Okamura M, Akizuki N, Nakano T, et al. Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology 2008; 17:154-160.
60. Trask PC. Assessment of depression in cancer patients. J Natl Cancer Inst Monogr 2004; 32:80-92.
61. Shimizu K, Akechi T, Shimamoto M, et al. Can psychiatric intervention improve major depression in very near end-of-life cancer patients? Palliat Support Care 2007; 5:3-9. This small study on 20 patients found a correlation between patients' survival time (more than one month) and response to psychiatric intervention.
62. MacLeod AD. Methylphenidate in terminal depression. J Pain Symptom Manage 1998; 16:193-198.
63. Sood A, Barton DL, Loprinzi CL. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care 2006; 23:35-40.
64. Sharpe M, Strong V, Allen K, et al. Management of major depression in out-patients attending a cancer center: a preliminaryevaluation of a multicomponent cancer nurse-delivered intervention. Br J Cancer 2004; 90:310-313.
65. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology 2007; 16:277-286. A randomized controlled trial of a specific psychotherapy (SEGP) in relaxation group of 147 breast cancer patients in comparison with a control group of only relaxation group (n = 80), which demonstrates efficiency of SEGP in prevention or treating depression but failed to improve survival.
66. Kissane DW, Bloch S, Smith GC, et al. Cognitive existential group psychotherapy for women with primary breast cancer: a randomized controlled trial. Psychooncology 2003; 12:532-546.
67. Savard J, Simard S, Giguère I, et al. Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliat Support Care 2006; 4:219-237.
68. Sherman AC, Pennington J, Latif U, et al. Patient preferences regarding cancer group psychotherapy interventions: a view from the inside. Psychosomatics 2007; 48:426-432.
69. Garland SN, Carlson LE, Cook S, et al. A nonrandomized comparison of mindfulness-based stress reduction and healing arts programs for facilitating posttraumatic growth and spirituality in cancer outpatients. Support Care Cancer 2007; 15:949-961.
70. Wilkinson SM, Love SB, Westcombe AM, et al. Effectiveness of aromatherapy massage in themanagement of anxietyanddepression inpatientswith cancer:a multicenter randomized controlled trial. J Clin Oncol 2007; 25:532-539.
71. Andersen BL, Farrar WB, Golden-Kreutz D, et al. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun 2007; 21:953-961. This is a clinical trial of 227 postsurgery breast cancer patients showing efficiency of a set of psychological interventions (weekly for 4 months and followed by monthly sessions for 8 months) in terms of behavioral changes, higher functional status and distress reduction.